Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at higher dose levels in participants with type 2 diabetes inadequately controlled on metformin, SGLT2i, or both (AMBITION 3)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525472-26-00

Enrollment

220

Registered

2026-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with type 2 diabetes

Brief summary

Change in glycated haemoglobin A1c (HbA1c)

Detailed description

Relative change in body weight, Change in glycated haemoglobin A1c (HbA1c), Change in triglycerides, Change in systolic blood pressure, Change in non-HDL cholesterol, Change in high-sensitivity C-reactive protein (hsCRP)

Interventions

DRUGNNC0487-0111 B 10142

DRUGNNC0487-0111 B 10144

DRUGPlacebo (semaglutide)

DRUGNNC0487-0111 B 10146

DRUGsemaglutide

DRUGzenagamtide B 10176

DRUGNNC0487-0111 B 10145

DRUGPlacebo (Zenagamtide)

DRUGNNC0487-0111 B 10143

DRUGNNC0487-0111 B 10141

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in glycated haemoglobin A1c (HbA1c)	—

Secondary

Measure	Time frame
Relative change in body weight, Change in glycated haemoglobin A1c (HbA1c), Change in triglycerides, Change in systolic blood pressure, Change in non-HDL cholesterol, Change in high-sensitivity C-reactive protein (hsCRP)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 24, 2026